The global blood-based biomarkers market is projected to grow from USD 8.5 billion in 2025 to USD 18.5 billion by 2034, driven by increasing demand for non-invasive diagnostics, rising chronic disease prevalence, and advances in genomics and liquid biopsy technologies. North America leads with 44% market share, while Asia-Pacific shows fastest growth. Key players include Roche, Abbott, Siemens Healthineers, and Thermo Fisher Scientific.

BCC Research's mid-year assessment highlights AI-driven discovery, precision oncology, and connected health as major growth themes in the life sciences sector. Key opportunities include smart inhalers with AI integration, genomic profiling platforms, cardiovascular drug innovations, and in vitro toxicity testing. The sector benefits from aging populations, regulatory support for non-animal testing, and emerging market expansion, though risks include patent expirations and reimbursement variability.

The global cancer biomarkers market is projected to grow from $25.9 billion in 2026 to $37.8 billion by 2035, with a CAGR of 4.3%. Growth is driven by rising cancer incidence, personalized medicine adoption, advances in NGS and liquid biopsy technologies, and increased biomarker-driven diagnostics. HER2 testing leads by biomarker type (21.1% share), while breast cancer testing dominates by indication (25.1% share). North America captures 52.1% of global market revenue.

The global ovarian cancer diagnostics market is valued at USD 4.92 billion in 2025 and is projected to reach USD 8.08 billion by 2035, growing at a CAGR of 5.06%. Growth is driven by rising ovarian cancer incidence, increasing adoption of AI-powered imaging, biomarker testing, and precision oncology diagnostics. North America leads with 41.2% market share, while imaging and hospital laboratories dominate their respective segments.

Grail, a leader in multi-cancer early detection (MCED) testing, could be poised for significant growth as its Galleri test shows promising clinical trial results. The company awaits FDA approval and potential insurance reimbursement, which could unlock a $50 billion market opportunity. However, the stock remains high-risk due to unprofitability and competition from larger players.

The global AI in cancer diagnostics market is experiencing rapid growth, projected to expand from $0.79 billion in 2025 to $0.96 billion in 2026 (20.2% CAGR), reaching $1.97 billion by 2030. Growth is driven by advancements in deep learning, AI-powered imaging systems, rising cancer prevalence, and collaborations between AI developers and medical institutions. Key developments include Lunit's $193 million acquisition of Volpara and launches of integrated AI diagnostic systems by companies like Dedalus and Ibex Medical Analytics.

Guardant Health received FDA approval for its Guardant360 Liquid CDx test, an expanded liquid biopsy panel that is now the largest FDA-approved in its category. The test evaluates a genomic footprint 100 times wider than the previous version, combines genomic and epigenomic insights from a single blood sample, and can deliver results in as little as seven days. The approval transfers seven previously approved companion diagnostic indications from the earlier Guardant360 CDx test. Shares rose 8.81% following the announcement.

The global colorectal cancer diagnostics and therapeutics market is projected to grow from USD 35 billion in 2025 to USD 73 billion by 2034 at a CAGR of ~9%. Growth is driven by rising colorectal cancer prevalence, increased screening awareness, advancements in non-invasive diagnostics (liquid biopsy, stool-based DNA tests), and emerging targeted therapies and immunotherapies. North America leads with 41% market share, while Asia-Pacific is the fastest-growing region.

The FDA approved VEPPANU (vepdegestrant), a first-of-its-kind PROTAC therapy developed by Pfizer and Arvinas for treating advanced breast cancer with ESR1 mutations. The Phase 3 VERITAC-2 trial showed vepdegestrant reduced disease progression risk by 43% compared to fulvestrant, with median PFS of 5 months versus 2.1 months. Guardant Health's Guardant360 CDx was also approved as a companion diagnostic for patient identification.

The global oncology biomarkers market is projected to grow from $17.3 billion in 2025 to $33.63 billion by 2030, with a CAGR of 14.3%. Growth is driven by rising cancer incidence, personalized oncology therapies, AI-driven biomarker discovery, liquid biopsy adoption, and early cancer detection focus. Key players include Roche, Novartis, and Thermo Fisher Scientific.

Praxis Precision Medicines (PRAX) has surged 685% over the past year, attracting an $80.5 million investment from Driehaus Capital Management. The clinical-stage biotech company recently submitted two FDA applications for therapies targeting essential tremor and rare developmental epilepsies. With $926 million in cash and potential revenue exceeding $20 billion if approved, the company is positioned for significant growth, though regulatory approval remains a key risk.

The FDA approved Guardant Health's Guardant360 CDx blood test as a companion diagnostic to identify patients with BRAF V600E-mutant metastatic colorectal cancer who may benefit from Pfizer's Braftovi treatment combined with cetuximab and chemotherapy. This marks the 25th companion diagnostic indication for the platform and expands non-invasive genomic testing access. Guardant Health stock surged 2.27% to $118.37, trading at a 52-week high with strong technical momentum.